Sanofi Reports Phase 2 Results for Efdoralprin Alfa in Alpha-1 Antitrypsin Deficiency
Sanofi announced that its Phase 2 Elevaate study showed efdoralprin alfa normalized and maintained functional AAT levels in patients with alpha-1 antitrypsin deficiency. All key secondary endpoints were met and the treatment was well tolerated.
benzinga.comSanofi reported results from its Phase 2 Elevaate study of efdoralprin alfa for alpha-1 antitrypsin deficiency. The study found that the treatment normalized and maintained functional AAT levels. All key secondary endpoints were met.
The safety profile was comparable to plasma-derived protein.
Three-weekly dosing achieved mean functional AAT trough levels three times greater than weekly plasma-derived protein. The treatment was well tolerated in the study.
Key Facts
Potential Impact
- 01
Further clinical development of efdoralprin alfa may be considered based on the Phase 2 results.
Transparency Panel
Related Stories
ibtimes.comSEC Chair Paul Atkins Says Congress Will Pass Crypto Legislation
SEC Chair Paul Atkins stated he is confident Congress will pass crypto market structure legislation. He added that President Trump will sign the bill into law.
asiaone.comIran Says Strait of Hormuz Management Belongs to Iran and Oman
Iran's Foreign Ministry spokesperson stated that control of the Strait of Hormuz must be decided solely by Iran and Oman. The spokesperson also said no agreement has been reached with the United States and that current focus remains on ending the war.
cnbc.comFed Official Highlights Regulatory Barriers to AI Productivity Gains
A Federal Reserve official stated that productivity growth remains key to economic expansion and that regulatory hurdles are the main obstacle to sustained gains from artificial intelligence.